Intended for healthcare professionals

Rapid response to:

Editorials

The Tamiflu trials

BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g2630 (Published 09 April 2014) Cite this as: BMJ 2014;348:g2630

Rapid Response:

Re: The Tamiflu trials

I am concerned that the BMJ is conflating the Tamiflu RCT data with their admirable aim of supporting open access to all trials data. The potential benefits of early treatment of influenza have become the first casualty in this "political" war, and I am afraid that patients who are eligible for treatment will wrongly be denied treatment with neuraminidase inhibitors as a result, to their significant potential detriment.

Those who are genuinely interested in considering evidence from all sources should read what the CDC have announced following publication of the Cochrane review (1). It clearly indicates the role that these drugs have in reducing mortality in severe influenza.

1. http://www.cdc.gov/media/haveyouheard/stories/Influenza_antiviral2.html

Competing interests: No competing interests

13 April 2014
Peter J Flegg
Consultant Physician
Blackpool Teaching Hospitals NHS Trust
Blackpool FY3 8NR